Tumor biomarkers: PSA and beyond

Melichar, Bohuslav

doi:10.1515/cclm-2012-0631

Cited by 5 publications

(5 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Both PSA velocity and PSA doubling time are used to monitor the recurrence of the tumour after treatment (D'Amico et al, 2004(D'Amico et al, , 2005. Again, some studies have compared the responses from PSA velocity and PSA doubling time with biopsy results demonstrating how these two PSA derivatives can fail the diagnosis (Melichar, 2012).…”

Section: Psa Velocity and Psa Doubling Timementioning

confidence: 99%

DNA aptamer-based detection of prostate cancer

2015

View full text Add to dashboard Cite

The use of aptamers in biosensing has attracted considerable attention as an alternative to antibodies because of their unique properties such as long-term stability, cost-effectiveness and adjustability to various applications. Among cancers, the early diagnosis of prostate cancer (PCa) is one of the greatest concerns for ageing men worldwide. One of the most commonly used biomarkers for PCa is prostate-specific antigen (PSA), which can be found in elevated levels in patients with cancer. This review presents the gradual transition of research from antibody-based to aptamerbased biosensors, specifically for PSA. A brief description on aptamer-based biosensing for other PCa biomarkers is also presented. Special attention is given to electrochemical methods as analytical techniques for the development of simple, sensitive and cost-effective biosensors. The review also focuses on the different surface chemistries exploited for fabrication and their applications in clinical samples. The use of aptamers represents a promising tool for the development of point-ofcare biosensors for the early detection of prostate cancer. In view of the unmatched upper hand of aptamers, future prospects are also discussed, not only in the point-of-care format but also in other novel applications.

show abstract

Section: Psa Velocity and Psa Doubling Timementioning

confidence: 99%

DNA aptamer-based detection of prostate cancer

2015

View full text Add to dashboard Cite

show abstract

“…PSA, a member of the family of kallikrein-related peptidases [8], is frequently used for the diagnosis and management of prostate cancer [9] and also as an outcome measure for relapsed disease [10] in prostate cancer trials. However, reliance on PSA kinetics alone may be misleading by several well-known mechanisms [11,12].…”

Section: Introductionmentioning

confidence: 99%

Androgen deprivation decreases prostate specific antigen in the absence of tumor: implications for interpretation of PSA results

Wenisch

Mayr

Spiel

et al. 2013

Clinical Chemistry and Laboratory Medicine (CCLM)

View full text Add to dashboard Cite

Background: Prostate-specific antigen (PSA) is used as an outcome measure for relapsed disease in prostate cancer. Nonetheless, there are considerable concerns about its indiscriminate use as a surrogate endpoint for cell growth or survival. We hypothesized that treatment with a luteinizing hormone releasing hormone (LHRH) analog would decrease PSA levels even in the absence of malignant disease. Methods: We determined testosterone and PSA levels in 30 healthy volunteers after a single intramuscular injection of a LHRH depot formulation. Testosterone and PSA levels were quantified by radioimmunoassay and electrochemi-luminescence immunoassay, respectively. Results: After an initial flare-up during the first 3 days testosterone decreased reaching castration levels in 18 of the 30 young men (60%). After the nadir on day 28, testosterone levels increased to normal again. Changes in PSA paralleled those of testosterone. Castration reduced PSA levels by 29% (95% CI 19%-39%) compared to baseline (p < 0.0001). Conclusions: LHRH superagonists decrease PSA levels by testosterone deprivation. Conferring these findings to tumor patients, decreases in PSA after treatment with LHRH analogs might not only reflect disease regression but also a direct testosterone mediated effect on PSA. Thus, PSA levels should be cautiously interpreted when patients receive hormonal therapy.

show abstract

“…Therefore, an ideal reference population for the diagnosis of acute myocardial infarction (AMI) should include a representative subset of clinically healthy subjects (both males and females, with broad age distribution), in whom coronary angiogram is negative. Another valuable example here is that of cancer biomarkers such as prostate specific antigen (PSA) and related measures [ 16 ], wherein the diagnostic cut-off values should be calculated using a reference population where the presence of benign disorders or small malignancies (e.g., in situ carcinomas) has been accurately ruled out by means of prostatic biopsy [ 17 ]. Anyone would know, however, that invasive testing is not routine practice for excluding individuals from reference range calculation.…”

mentioning

confidence: 99%